Compare TG Therapeutics Inc (TGTX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wix.Com Ltd — how do they compare? TG Therapeutics Inc trades at $55 (market cap $8.16B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: TG Therapeutics Inc is far larger — about 2.6× Wix.Com Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Wix.Com Ltd for 62 Days on average.
| TGTX | WIX | |
|---|---|---|
Market Cap | $8.16B | $3.11B |
Volume | 1,735,121 | 809,286 |
Sector | Health | Technology |
52-Week High | $59.06 | $145.54 |
52-Week Low | $26.94 | $40.43 |
Typical Hold Time | 16 Days | 62 Days |
Enterprise Value | $8.37B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Wix.com (WIX) trades at $76.56, up 4.92% in the last 24 hours, with technical indicators showing a neutral to bullish bias. Revenue growth is robust, reaching $1.99B in 2025, but profitability is inconsistent, with a net income margin of -8.19% in 2026. Analyst sentiment is positive, with a consensus buy rating and a $77 price target, though recent class action lawsuits add caution.
The outlook for WIX hinges on sustaining revenue growth while improving profitability. Risks include legal challenges and volatile earnings, but strong analyst support and a solid market position offer potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
